MedTrace Logo

S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate

NCT00030901 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 619

Last updated 2013-02-06

Study results available
· View outcomes & findings →

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of selenium may be an effective way to prevent prostate cancer in patients who have neoplasia of the prostate.

PURPOSE: Randomized phase III trial to study the effectiveness of selenium in preventing prostate cancer in patients who have neoplasia of the prostate.

Conditions

Interventions

DRUG

L-selenomethionine

Randomization between active L-selenomethionine and placebo

DRUG

L-selenomethionine placebo

Randomization between active L-selenomethionine and placebo

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    collaborator NETWORK

  • Cancer and Leukemia Group B

    collaborator NETWORK

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Jim Marshall, PhD · Roswell Park Cancer Institute

  • David Jarrard, MD · University of Wisconsin, Madison

  • W. Robert Lee, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-02-29
Primary Completion
2011-11-30
Completion
2011-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030901 on ClinicalTrials.gov